natgillin/translations-raw huggingface dataset:
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel.
Nema dokaza da drugi lijekovi koji smanjuju lučenje želučane kiseline, poput H2 blokatora (osim cimetidina koji je inhibitor CYP2C19) ili antacida, utječu na antitrombocitnu aktivnost klopidogrela.
Magyarország Teva Magyarország Zrt Tel.: +36 1 288 64 00
Magyarország Teva Gyógyszergyár Zrt Tel.: +36 1 288 64 00
Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see section 5.1).
Rezultati kliničkih ispitivanja podupiru trajanje liječenja do 12 mjeseci, a najveći učinak zabilježen je u trećem mjesecu liječenja (vidjeti dio 5.1.).
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
Učinak na jetrene metaboličke enzime nije primijećen u ljudi koji su primali terapijske doze klopidogrela.
A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Ostali lijekovi: Provedene su određene kliničke studije s klopidogrelom i nekim drugim istodobno primjenjivanim lijekovima kako bi se ispitala mogućnost farmakodinamičkih i farmakokinetičkih interakcija.
What Clopidogrel Teva Generics B.V. looks like and contents of the pack The film-coated tablets are pink, round and slightly convex.
Kako Klopidogrel Teva Generics B.V. izgleda i sadržaj pakiranja Filmom obložene tablete su ružičaste, okrugle i blago ispupčene.
België/Belgique/Belgien
Luxembourg/Luxemburg
Platelets are very small structures in the blood, which clump together during blood clotting.
Trombociti su vrlo mala krvna tjelešca, tzv. krvne pločice, koje se nakupljaju tijekom zgrušavanja krvi.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.
Ako je potrebno hitno korigirati produljeno vrijeme krvarenja, transfuzija trombocita može smanjiti učinak klopidogrela.
If you become pregnant while taking Clopidogrel Teva Generics B.V., consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Ako zatrudnite za vrijeme uzimanja lijeka Klopidogrel Teva Generics B.V., odmah se posavjetujte s liječnikom jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
In vitro, this metabolic pathway is mediated by CYP3A4, CYP2C19, CYP1A2 and CYP2B6.
Ovaj metabolički put u in vitro uvjetima posredovan je enzimima CYP3A4, CYP2C19, CYP1A2, i CYP2B6.
Repeated doses of 75 mg per day produced substantial inhibition of ADP-induced platelet aggregation from the first day; this increased progressively and reached steady state between Day 3 and Day 7.
Ponovljene doze klopidogrela od 75 mg na dan uzrokuju snažnu inhibiciju ADP-om posredovane agregacije trombocita od prvoga dana; to se progresivno pojačava i dostiže stanje dinamičke ravnoteže između dana 3 i dana 7.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine.
Krvarenje se može pojaviti u obliku krvarenja u želucu ili crijevima, modrica, hematoma (neuobičajeno krvarenje ili modrica ispod kože), krvarenja iz nosa, krvi u mokraći.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day).
Nije bilo dokaza o karcinogenim učincima kad se klopidogrel davao miševima 78 tjedana i štakorima 104 tjedna u dozama do 77 mg/kg na dan (što predstavlja barem 25 puta veću izloženost nego u ljudi koji primaju kliničku dozu od 75 mg/dan).
NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
Nesteroidni protuupalni lijekovi (NSAIL): u jednoj kliničkoj studiji provedenoj na zdravim dobrovoljcima, istodobna primjena klopidrogela i naproksena povećala je gubitak krvi okultnim krvarenjem iz probavnog trakta.
No antidote to the pharmacological activity of clopidogrel has been found.
Nije pronađen antidot za farmakološku aktivnost klopidogrela.
For the 28x1 tablets pack size, you can check the day on which you last took the tablet by referring to the calendar printed on the blister.
Na pakiranju od 28x1 tableta možete pomoću kalendara otisnutog na blisteru provjeriti dan kada ste zadnji put uzeli tabletu Klopidogrel Teva Generics B.V.
Thrombotic Thrombocytopenic Purpura (TTP)
Trombotična trombocitopenična purpura (TTP)
WHAT CLOPIDOGREL TEVA GENERICS B.V. IS AND WHAT IT IS USED FOR
Što je Klopidogrel Teva Generics B.V. i za što se koristi
You should take Clopidogrel Teva Generics B.V. for as long as your doctor continues to prescribe it.
Klopidogrel Teva Generics B.V. trebate uzimati sve dok Vam ga liječnik propisuje.
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge.
Za bolesnike kojima nije učinjena angiografija primarni ishod bio je smrt ili ponovljeni infarkt miokarda do osmog dana liječenja ili do otpusta iz bolnice.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other drugs, not all patients will have adequate platelet inhibition.
Budući da se aktivni metabolit klopidogrela stvara pomoću enzima CYP450, od kojih su neki polimorfni ili podložni inhibiciji drugim lijekovima, svi bolesnici neće imati adekvatnu inhibiciju trombocita.
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively.
Klopidogrel je značajno smanjio relativni rizik od smrti bilo kojeg uzroka za 7% (p=0,029) i relativni rizik kombinacije ponovljenog infarkta, moždanog udara ili smrti za 9% (p=0,002), što je značilo ukupno smanjenje rizika od 0,5% odnosno 0,9%.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
S obzirom na to da nema dovoljno podataka o primjeni klopidogrela u trudnica, preporučljivo je, kao mjera opreza, ne koristiti klopidogrel za vrijeme trudnoće.
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Teva Generics B.V..
Kao mjera opreza, treba prestati s dojenjem za vrijeme liječenja lijekom Klopidogrel Teva Generics B.V.
Read all of this leaflet carefully before you start taking this medicine.
Pažljivo pročitajte cijelu uputu prije nego što počnete uzimati ovaj lijek jer sadrži Vama važne podatke.
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies.
Podaci prijavljeni iz opservacijskih i iz kliničkih studija o kliničkim implikacijama ove farmakokinetičke (PK)/farmakodinamičke (PD) interakcije u smislu značajnih kardiovaskularnih događaja nisu konzistentni.
Each film-coated tablet contains 13 mg hydrogenated castor oil.
Jedna filmom obložena tableta sadrži 13 mg hidrogeniranog ricinusovog ulja.
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake.
Međutim, istodobna primjena 500 mg ASK dva puta na dan tijekom jednog dana nije značajno produljila vrijeme krvarenja već produljeno uzimanjem klopidogrela.
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction.
U podskupini s infarktom miokarda većina je bolesnika prvih nekoliko dana nakon akutnog infarkta miokarda primala ASK.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘Possible side effects')
Ako ste ipak zabrinuti zbog krvarenja, odmah obavijestite svog liječnika (vidjeti dio 4. "Moguće nuspojave").
In addition to clinical studies experience, adverse reactions have been spontaneously reported.
Uz iskustvo iz kliničkih ispitivanja, nuspojave su prijavljivane i spontano.
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
Karakteriziraju je trombocitopenija i mikroangiopatska hemolitička anemija kojoj mogu biti pridruženi neurološki ispadi, disfunkcija bubrega ili vrućica.
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics).
Prevalencija CYP2C19 alela koji rezultiraju umjerenim i slabim CYP2C19 metabolizmom razlikuje se prema rasi/etničkoj skupini (vidjeti dio "Farmakogenetika").
• if you have a risk of bleeding such as - a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) - a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) - a recent serious injury - a recent surgery (including dental) - a planned surgery (including dental) in the next seven days
Ako postoji opasnost od krvarenja poput - medicinskih stanja kod kojih postoji opasnost od unutrašnjeg krvarenja (kao što je želučani čir), - poremećaja krvi zbog čega ste skloni unutrašnjim krvarenjima (krvarenje u tkivima, organima ili zglobovima), - nedavne teške ozljede, - nedavnog kirurškog zahvata (uključujući stomatološke zahvate), - planiranog kirurškog zahvata (uključujući stomatološke zahvate) u sljedećih sedam dana.
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours.
Taj učinak je bio dosljedan u odnosu na dob, spol i primjenu fibrinolitika i opažen je unutar 24 sata.
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins.
Fibrinolitike je primalo 99,7% bolesnika (fibrin-specifični: 68,7%, fibrin-nespecifični: 31,1%), 89,5% heparin, 78,7% beta blokatore, 54,7% ACE inhibitore i 63% statine.
See leaflet for further information.
Vidjeti Uputu o lijeku za dodatne informacije.
The CYP2C19*2 and CYP2C19*3 alleles account for 85% of reduced function alleles in whites and 99% in Asians.
CYP2C19*2 i CYP2C19*3 aleli čine većinu alela sa smanjenom funkcijom u slabih metabolizatora u bijelaca (85%) i Azijata (99%).
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU LIJEKA
3542 DR Utrecht The Netherlands
Computerweg 10 3542 DR Utrecht Nizozemska
Bleeding and haematological disorders
Krvarenje i hematološki poremećaji
Clopidogrel Teva Generics B.V. belongs to a group of medicines called antiplatelet medicinal products.
Klopidogrel Teva Generics B.V. sadrži klopidogrel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
The use of clopidogrel in CURE was associated with a decrease in the need of thrombolytic therapy (RRR=43.3%; CI: 24.3%, 57.5%) and GPIIb/IIIa inhibitors (RRR=18.2%; CI: 6.5%, 28.3%).
Primjena klopidogrela u studiji CURE bila je povezana sa smanjenjem potrebe za trombolitičkom terapijom (RRR = 43,3%; CI: 24,3%, 57,5%) i inhibitorima GPIIb/IIIa (RRR = 18,2%; CI: 6,5%,
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
Novi su kardiovaskularni događaji (primarni ishod) spriječeni, sa smanjenjem relativnoga rizika od 22% (CI: 8,6, 33,4), 32% (CI: 12,8, 46,4), 4% (CI: -26,9, 26,7), 6% (CI: -33,5, 34,3) i 14% (CI: -31,6, 44,2) tijekom studijskih razdoblja od 0 do 1 mjesec, 1 do 3 mjeseca, 3 do 6 mjeseci, 6 do 9 mjeseci, odnosno 9 do 12 mjeseci.
If you have experienced severe chest pain (unstable angina or heart attack), your doctor may give you 300 mg of Clopidogrel Teva Generics B.V. (4 tablets of 75 mg) once at the start of treatment.
Ako ste imali jake bolove u prsištu (nestabilna angina ili srčani udar), liječnik Vam u početku liječenja može jednokratno dati 300 mg lijeka Klopidogrel Teva Generics B.V (4 tablete of 75 mg).
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.
Apsorpcija iznosi najmanje 50%, na temelju izlučivanja metabolita klopidogrela putem mokraće.
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
Heparin: u jednoj kliničkoj studiji provedenoj na zdravim ispitanicima, primjena klopidogrela nije iziskivala promjenu doze heparina, niti je mijenjala učinak heparina na koagulaciju.
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
In vitro i in vivo, klopidogrel se metabolizira kroz dva glavna metabolička puta: jednim posredovanim esterazom, koji dovodi do hidrolize u neaktivni derivat karboksilne kiseline (koji čini 85% cirkulirajućih metabolita) i drugim posredovanim višestrukim enzimima skupine citokroma P450.
The safety and efficacy of clopidogrel have been evaluated in 4 double-blind studies involving over 80,000 patients: the CAPRIE study, a comparison of clopidogrel to ASA, and the CURE, CLARITY and COMMIT studies comparing clopidogrel to placebo, both medicinal products given in combination with ASA and other standard therapy.
Sigurnost primjene i djelotvornost klopidogrela procijenjena je u 5 dvostrukoslijepih studija koje su uključivale više od 88 000 bolesnika: studija CAPRIE, u kojoj su uspoređivani klopidogrel i ASK, te studije CURE, CLARITY, COMMIT i ACTIVE-A u kojima je uspoređivano djelovanje klopidogrela u odnosu na placebo, a obje su terapije davane u kombinaciji s ASK i drugom standardnom terapijom.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used.
Ovaj učinak bio je dosljedno prisutan u svim prethodno određenim podskupinama koje su uključivale dob i spol bolesnika, lokaciju infarkta i tip primijenjenog fibrinolitika ili heparina.
Animal studies have shown excretion of clopidogrel in breast milk.
Ispitivanja na životinjama pokazala su da se klopidogrel izlučuje u mlijeko.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4).
Inhibitori glikoproteina IIb/IIIa: klopidogrel se s oprezom mora davati bolesnicima koji istodobno primaju inhibitore glikoproteina IIb/IIIa (vidjeti dio 4.4.).
Very rare
Manje često
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
- Akutni infarkt miokarda s elevacijom ST-segmenta, u kombinaciji s ASK u medikamentozno liječenih bolesnika pogodnih za liječenje trombolitičkom terapijom.
For patients over 75 years of age clopidogrel should be initiated without a loading dose.
U bolesnika starijih od 75 godina liječenje klopidogrelom ne treba započinjati udarnom dozom.
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor.
Liječnik će Vam propisati i acetilsalicilatnu kiselinu (tvar koju sadrže mnogi lijekovi za ublažavanje boli i snižavanje povišene temperature, kao i oni za sprječavanje stvaranja krvnih ugrušaka).
You have been prescribed Clopidogrel Teva Generics B.V. to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease, or - You have experienced a severe type of chest pain known as ‘unstable angina' or ‘myocardial infarction' (heart attack).
Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer: - imate otvrdnuće arterija (koje se još zove ateroskleroza) - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija, ili - ste imali teški oblik boli u prsištu, poznat pod nazivom „nestabilna angina“ ili „infarkt miokarda“ (srčani udar).
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
POSEBNO UPOZORENJE O ČUVANJU LIJEKA IZVAN POGLEDA
At very high doses, a poor gastric tolerability (gastritis, gastric erosions and/or vomiting) of clopidogrel was also reported in rat and baboon.
Pri vrlo visokim dozama, također je zabilježena slaba želučana podnošljivost klopidogrela (gastritis, erozije želuca i/ili povraćanje) u štakora i babuna.
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT.
U bolesnika s akutnim infarktom miokarda sa ST elevacijom (STEMI), sigurnost primjene i djelotvornost klopidogrela procijenjena je u 2 randomizirane, dvostrukoslijepe, placebom kontrolirane studije, CLARITY i COMMIT.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Klopidogrel ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
Tako se, nakon 3 mjeseca, zabilježena korist liječenja kombinacijom klopidogrela + ASK nije dalje povećavala, dok je opasnost od krvarenja i nadalje postojala (vidjeti dio 4.4.).
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Ovaj lijek sadrži hidrogenirano ricinusovo ulje koje može uzrokovati probavne tegobe i proljev.
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Studija CAPRIE uključivala je 19 185 bolesnika s aterotrombozom koja se manifestirala kao nedavni infarkt miokarda (<35 dana), nedavni ishemijski moždani udar (između 7 dana i 6 mjeseci) ili utvrđena bolest perifernih arterija (BPA).
Within each system organ class, adverse drug reactions are presented in order of decreasing seriousness.
Unutar svakog organskog sustava nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects')
Također, odmah obavijestite svog liječnika ako se pojavi medicinsko stanje (koje se naziva "trombotična trombocitopenična purpura" ili "TTP") sa simptomima koji uključuju vrućicu i potkožne modrice koje se mogu pojaviti kao crvene točkice, sa ili bez neobjašnjivog teškog umora, zbunjenosti i žute boje kože ili očiju (žutica) (vidjeti dio 4. "Moguće nuspojave").
Overdose following clopidogrel administration may lead to prolonged bleeding time and subsequent bleeding complications.
Predoziranje klopidogrelom može produljiti vrijeme krvarenja i naknadno dovesti do komplikacija s krvarenjem.
The CLARITY trial included 3,491 patients presenting within 12 hours of the onset of a ST elevation MI and planned for thrombolytic therapy.
Ispitivanje CLARITY uključivalo je 3491 bolesnika, koji su unutar 12 sati imali infarkt miokarda s elevacijom ST-spojnice i planirala im se trombolitička terapija.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes.
One su se javljale pri dozama koje su bile barem 25 puta veće od izloženosti u bolesnika koji su primali kliničku dozu od 75 mg klopidogrela na dan i bile su posljedice učinka na jetrene metaboličke enzime.
Other alleles associated with reduced metabolism include CYP2C19*4, *5, *6, *7, and *8, but these are less frequent in the general population.
Ostali aleli povezani s odsutnim ili smanjenim metabolizmom uključuju CYP2C19*4, *5, *6, *7 i *8, ali oni su manje zastupljeni.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover.
Zbog ireverzibilnog vezanja, izloženi trombociti zahvaćeni su ovim učinkom do kraja svog životnog vijeka (oko 7-10 dana), a normalna funkcija trombocita obnavlja se brzinom koja odgovara brzini stvaranja novih trombocita.
What Clopidogrel Teva Generics B.V. is and what it is used for Before you take Clopidogrel Teva Generics B.V. How to take Clopidogrel Teva Generics B.V.
Što je Klopidogrel Teva Generics B.V. i za što se koristi Što morate znati prije nego što počnete uzmati Klopidogrel Teva Generics B.V.
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
Aktivni metabolit klopidogrela selektivno inhibira vezanje adenozin difosfata (ADP) za njegov receptor P2Y12 na trombocitima te posljedično i ADP-om posredovano aktiviranje kompleksa GPIIb/IIIa, inhibirajući na taj način agregaciju trombocita.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital, or oestrogen.
Nadalje, na farmakodinamičku aktivnost klopidogrela nije značajno utjecala istodobna primjena fenobarbitala ili estrogena.
- This medicine has been prescribed for you.
- Ovaj je lijek propisan samoVama.
After repeated doses of 75 mg clopidogrel per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects.
Nakon ponovljenih dnevnih doza klopidogrela od 75 mg tijekom deset dana, u bolesnika s teško oštećenom funkcijom jetre inhibicija ADP-om inducirane agregacije trombocita bila je slična u usporedbi sa zdravim ispitanicima.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Teva Generics B.V..
Ako ste trudni ili sumnjate na trudnoću, obavijestite svog liječnika ili ljekarnika prije nego što uzmete Klopidogrel Teva Generics B.V.
A pharmacodynamic interaction between clopidogrel and acetylsalicylic acid is possible, leading to increased risk of bleeding.
Farmakodinamička interakcija između klopidogrela i acetilsalicilatne kiseline moguća je i ona može povećati rizik od krvarenja.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing.
C u ljudi, približno 50% doze izlučilo se u mokraću, a približno 46% u stolicu u intervalu od 120 sati nakon doziranja.
LIST OF EXCIPIENTS It also contains hydrogenated castor oil.
POPIS POMOĆNIH TVARI Također sadrži: hidrogenirano ricinusovo ulje.